In the present study using cell culture and xenograft mouse models, we found that inhibition of the CDK4/6-cyclin D-Rb pathway by ribociclib augmented the efficacy of 5-FU and IFN-α and displayed selective anti-RCC activity. Here, CDK4 is linked to renal cell carcinoma.